Jatenzo Pediatric (Under 12) Dosing: What Clinicians Need to Know

What the FDA Label Actually Says About Jatenzo in Pediatric Patients

The FDA label for Jatenzo contains a direct contraindication for use in pediatric patients, with no approved dosing protocol for children under 18, and no weight-based or age-stratified dosing table for those under 12. This is not a gray area.

The prescribing information states that androgens, including testosterone undecanoate, should not be used in children and adolescents because of the risk of virilization, premature epiphyseal closure, and disruption of normal hypothalamic-pituitary-gonadal axis development. The FDA approved Jatenzo in March 2019 solely for adult men with hypogonadism caused by certain medical conditions, including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). View the FDA approval record at accessdata.fda.gov.

Why No Pediatric Dose Exists for Jatenzo

Jatenzo was never submitted to the FDA with pediatric clinical data in the under-12 population. No Phase 2 or Phase 3 trial has enrolled prepubertal children on oral testosterone undecanoate in the United States under a formal IND for this indication.

The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to assess drugs in pediatric populations under certain conditions, but endocrine therapies targeting sex-hormone replacement have historically received waivers when the condition does not occur in that age group in the same clinical presentation. Primary hypogonadism in children under 12 is rare, managed through specialist pathways, and the risk-benefit profile differs substantially from adults. The FDA provides PREA guidance here.

Regulatory Context: Other Testosterone Products in Pediatrics

No oral testosterone product is FDA-approved for children under 12 in the United States. Injectable testosterone enanthate and testosterone cypionate have off-label use histories in adolescent males with delayed puberty, typically initiated at age 14 or later and only after a confirmed bone age delay. The Endocrine Society's clinical practice guideline on testosterone therapy notes that androgen therapy for delayed puberty should begin at the lowest effective dose, with bone age surveillance every 6 months. Full guideline available via PubMed.

The Adult Dosing Evidence Base: Swerdloff et al. 2020

Understanding why adult dosing cannot be extrapolated downward requires a clear picture of the clinical pharmacology data that exists. The key trial for Jatenzo was published by Swerdloff et al. In the Journal of Clinical Endocrinology and Metabolism in 2020. Read the study on PubMed.

Study Design and Results

The Swerdloff trial enrolled adult men with documented hypogonadism (baseline serum testosterone <300 ng/dL on two separate morning measurements). Participants started at 237 mg oral testosterone undecanoate twice daily with food. Doses were titrated to 158 mg or 396 mg twice daily based on serum testosterone levels measured at day 90.

At 3 months, 87% of patients achieved serum testosterone within the eugonadal range (300 to 1,000 ng/dL). Mean serum testosterone on day 90 was approximately 462 ng/dL. These results established the starting dose of 237 mg twice daily as the current FDA-approved adult initiation dose.

Why These Numbers Don't Translate to Children Under 12

A 237 mg dose of oral testosterone undecanoate is designed for adult male pharmacokinetics. Body weight in prepubertal children under 12 ranges roughly from 18 to 40 kg compared to the adult male mean of 80 to 90 kg. Even a simple linear weight-based scaling would suggest doses in the range of 50 to 100 mg per administration, but no such dosing has been validated, and the pharmacokinetics of oral testosterone undecanoate in children differ because of differences in intestinal lymphatic absorption, fat intake per kilogram, and hepatic first-pass dynamics that have not been characterized in this population. Scaling an adult dose for a 25 kg child is not merely arithmetic. It requires population pharmacokinetic modeling data that does not yet exist for Jatenzo.

Risks Specific to Children Under 12

Testosterone exposure in prepubertal and early-pubertal children carries risks that do not apply to adult men. Each of the following concerns is backed by decades of endocrine literature and is listed in the Jatenzo prescribing information under "Warnings and Precautions."

Premature Epiphyseal Closure

Androgen excess accelerates bone maturation through estrogen produced via aromatization of testosterone. In children under 12, whose growth plates remain open, even short-term androgen exposure can advance bone age faster than chronological age, reducing final adult height. A 2017 review in the Journal of Clinical Endocrinology and Metabolism documented that untreated androgen excess in prepubertal boys with congenital adrenal hyperplasia caused bone ages 2 to 4 years ahead of chronological age in a majority of cases. Relevant background on androgen effects and bone age available via PubMed.

Irreversible Virilization

In children under 12, testosterone exposure can cause permanent clitoral or penile enlargement, premature pubic and axillary hair, acne, and changes in voice pitch. Some of these effects are not reversible on discontinuation.

Suppression of the Hypothalamic-Pituitary-Gonadal Axis

Exogenous testosterone suppresses LH and FSH secretion. In a child whose hypothalamic-pituitary-gonadal axis is still completing its developmental programming, this suppression may disrupt the normal pubertal tempo and potentially impair future fertility. The Endocrine Society guideline on male hypogonadism explicitly states: "Testosterone therapy is contraindicated in men (or boys) who want to preserve fertility in the near term." The same principle applies with even greater urgency to prepubertal boys. See the 2018 Endocrine Society guideline.

Cardiovascular and Hematologic Considerations

Jatenzo carries a black-box warning for blood pressure elevation. In the Swerdloff 2020 trial, mean systolic blood pressure increased by approximately 3.5 mmHg from baseline in adult participants. In children, blood pressure norms are age-, sex-, and height-stratified, making cardiovascular risk monitoring even more complex. Polycythemia risk (hematocrit elevation) is an additional concern because pediatric hematocrit reference ranges differ from those used to trigger dose modification in adults.

When Testosterone Therapy Is Considered in Boys Under 12

Very rare clinical scenarios may prompt a specialist to consider androgens in a male child under 12. These include:

• Micropenis in infancy, where low-dose topical or injectable testosterone is sometimes used under strict specialist supervision in the neonatal or early childhood period.
• Severe primary hypogonadism (bilateral anorchia, for example) where complete androgen absence poses its own developmental risks.
• Delayed puberty with extreme bone age delay in children approaching the upper end of the under-12 range, evaluated case by case.

In none of these scenarios is Jatenzo the agent of choice. Short-course injectable testosterone enanthate (25 to 50 mg intramuscularly every 4 weeks for 3 to 6 months) has the longest off-label use history in pediatric endocrinology for these purposes. Oral testosterone undecanoate, because of its food-dependent lymphatic absorption mechanism and less predictable pharmacokinetics compared to injectable formulations, is not the preferred vehicle in children.

The HealthRX pediatric testosterone decision framework below summarizes the recommended specialist pathway for any child under 12 presenting with suspected hypogonadism or androgen deficiency.

Step 1. Confirm diagnosis with two morning serum testosterone measurements drawn before 10 AM, plus LH, FSH, and bone age X-ray of the left hand and wrist.

Step 2. Refer to a board-certified pediatric endocrinologist before any testosterone prescription is written.

Step 3. If therapy is initiated, document informed consent (or assent plus parental consent) explicitly noting the off-label nature of any testosterone product in this age group.

Step 4. Obtain bone age X-ray every 6 months during therapy. Stop or taper if bone age advances more than 1 year per calendar year of treatment.

Step 5. Do not prescribe Jatenzo for this population. Select an injectable or topical formulation with established pediatric dosing literature and a shorter half-life that allows for rapid discontinuation if adverse effects emerge.

Jatenzo Adult Dosing: The Approved Protocol for Reference

While no pediatric protocol exists for Jatenzo, clinicians treating adult males or transitioning adolescents to adult care should understand the approved adult dosing schedule, since it establishes the pharmacokinetic floor from which no pediatric extrapolation should proceed.

Starting Dose

The FDA-approved initiation dose is 237 mg (one capsule) taken orally twice daily with food. Both doses should be taken with a meal. Fat content in the meal is clinically meaningful. Jatenzo's absorption depends on intestinal lymphatic uptake of the lipophilic testosterone undecanoate ester. A low-fat meal reduces peak testosterone exposure by a clinically significant margin. The FDA labeling document is available at accessdata.fda.gov.

Dose Titration

After 90 days at the starting dose, a serum testosterone level is drawn as a mid-dose concentration (approximately 4 to 6 hours after the morning dose or at any time during the dosing interval). Dose adjustment targets are:

| Serum Testosterone Level | Dose Adjustment | |---|---| | <300 ng/dL | Increase to 396 mg twice daily | | 300 to 1,000 ng/dL | Maintain current dose (237 mg twice daily) | | >1,000 ng/dL | Decrease to 158 mg twice daily |

The minimum dose is 158 mg twice daily. The maximum is 396 mg twice daily. These thresholds are for adult men only.

Blood Pressure Monitoring

Because of the black-box warning, blood pressure must be checked before initiating Jatenzo and monitored throughout therapy. The label recommends that Jatenzo not be started in patients with pre-existing uncontrolled hypertension. For adult patients, the American Heart Association defines hypertension as a systolic reading of 130 mmHg or higher or a diastolic reading of 80 mmHg or higher. See the AHA 2017 guideline at ahajournals.org.

Monitoring Requirements If Off-Label Use Is Pursued (Specialist Context Only)

If a pediatric endocrinologist, operating outside the context of approved labeling and within a formal informed-consent and IRB-approved or compassionate-use framework, ever considers any testosterone product for a child under 12, the following monitoring parameters are the minimum accepted standard of care based on Endocrine Society guidance. Guideline reference via PubMed.

Laboratory Monitoring

• Serum total testosterone (trough and peak) at baseline and every 3 months.
• Complete blood count including hematocrit at baseline, 3 months, and every 6 months thereafter. Polycythemia (hematocrit >54% in adults; age-adjusted thresholds apply in children) requires dose reduction or discontinuation.
• LH and FSH at baseline and at 6-month intervals to assess degree of axis suppression.
• Lipid panel at baseline and annually, given androgen effects on HDL cholesterol.

Bone Age and Growth Monitoring

Bone age radiograph of the left hand and wrist at baseline, then every 6 months. Height velocity tracking with stadiometer measurements at every visit. Predicted adult height should be calculated using the Bayley-Pinneau method at each bone age assessment. If bone age advances faster than 1 year per calendar year of treatment or if predicted adult height declines by more than 2 cm, therapy should be discontinued.

Psychological and Behavioral Monitoring

Testosterone exposure accelerates behavioral as well as physical development. Children under 12 receiving any androgen require assessment for mood changes, aggression, and academic or social changes at every clinical visit. Parents and teachers should be included in this evaluation through structured questionnaires.

Formulation Considerations: Why Oral Testosterone Undecanoate Is Particularly Unsuitable for Under-12 Use

Oral testosterone undecanoate's absorption mechanism depends on co-ingestion with fat-containing food. The intestinal lymphatic pathway that bypasses hepatic first-pass metabolism requires adequate dietary fat to form chylomicron particles that carry the drug into the lymphatic system. Children under 12 have variable and often lower dietary fat intake relative to body weight, making plasma testosterone levels even harder to predict than in adults. Peak-to-trough variability in adults on Jatenzo is already wide (coefficient of variation for C-max reported at approximately 50% in pharmacokinetic sub-studies of the Swerdloff trial). In a child with inconsistent meal patterns, this variability would likely be even greater, increasing the risk of both supratherapeutic peaks causing accelerated bone age and subtherapeutic troughs failing to achieve the therapeutic goal. Swerdloff et al. Pharmacokinetic data available at PubMed.

Referring a Pediatric Patient: Practical Guidance for Primary Care

A primary care provider or general practice clinician who receives a request or referral question about Jatenzo dosing in a child under 12 should take the following steps.

Confirm the clinical concern. Is this a question about delayed puberty, suspected hypogonadism, a congenital condition such as Klinefelter syndrome or anorchia, or another presentation? Each has a distinct evaluation pathway.

Order the appropriate initial workup before referral: serum LH, FSH, testosterone (drawn before 10 AM), karyotype if Klinefelter syndrome is suspected, and a bone age X-ray. This speeds the specialist evaluation significantly.

Refer to a board-certified pediatric endocrinologist affiliated with a children's hospital or academic medical center. The American Academy of Pediatrics and the Pediatric Endocrine Society both maintain member directories for locating specialists.

Do not write a Jatenzo prescription while awaiting the referral. There is no approved dose, no validated dosing table, and no safety data supporting its use in children under 12. The risk of harm from premature bone closure alone is a sufficient reason to wait for specialist guidance.